WO2019107389A1 - 免疫チェックポイント阻害剤による抗腫瘍効果を増強するための医薬組成物 - Google Patents
免疫チェックポイント阻害剤による抗腫瘍効果を増強するための医薬組成物 Download PDFInfo
- Publication number
- WO2019107389A1 WO2019107389A1 PCT/JP2018/043704 JP2018043704W WO2019107389A1 WO 2019107389 A1 WO2019107389 A1 WO 2019107389A1 JP 2018043704 W JP2018043704 W JP 2018043704W WO 2019107389 A1 WO2019107389 A1 WO 2019107389A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- group
- antibody
- immune checkpoint
- checkpoint inhibitor
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a novel use of 5-aminolevulinic acid (hereinafter also referred to simply as "ALA") or a derivative thereof, specifically, 5-aminolevulinic acid or its derivative for enhancing the antitumor effect of an immune checkpoint inhibitor. It relates to the use of derivatives.
- ALA 5-aminolevulinic acid
- derivatives specifically, 5-aminolevulinic acid or its derivative for enhancing the antitumor effect of an immune checkpoint inhibitor. It relates to the use of derivatives.
- Tumors generated in the human body are usually removed prior to growth to an adverse effect on the human body by the underlying immune mechanisms.
- the following phenomena are known as this mechanism. That is, proteins specific to cancer cells (tumor antigens) bind to proteins called class I MHC molecules in cancer cells and are presented on the cell surface.
- the T cell recognizes that the cell is a cancer cell by the binding of the class I MHC and the tumor antigen to a TCR (T Cell Receptor) protein on the surface of T cell responsible for immunity.
- T cells that have recognized cancer cells begin to proliferate and damage cancer cells presenting tumor antigens.
- PD-L1 when cancer cells express a membrane protein called PD-L1 together with class I MHC, by binding to a membrane protein called PD-1 expressed in T cells, the above-mentioned activation of T cells is suppressed It is known to do. Since cancer cells that originally acquired an immune evasion mechanism for suppressing excessive immunity continue to proliferate, it is a new anticancer drug target to inhibit the binding of PD-L1 and PD-1 It has been noted as (Patent Document 1). PD-L1 is also expressed in “professional antigen-presenting cells” such as dendritic cells that specialize in presenting antigens to T cells.
- anti-PD-1 antibody nivolumab OZIVO (registered trademark)
- pembrolizumab Qiatoruda (registered trademark)
- anti-PD-L1 antibody is also atezolizumab, dulbalumab, Avelumab (Babenchio (registered trademark)) and the like have been developed and put into practical use.
- the anti-tumor effect of anti-PD-1 antibody is related to the generation of reactive oxygen in T cells, and the anti-tumor effect is intracellular signal transduction and mitochondrial activation by addition of a low concentration of a reactive oxygen generator.
- the anti-tumor effect of the anti-PD-1 antibody is enhanced even with a pharmaceutical that mimics intracellular signal transduction at this time (Non-patent Document 3).
- ALA or a derivative thereof enhances heme and cytochrome in the mitochondria of a cancer cell or a nucleus of a cell which has become abnormal to become a cancer cell, and the mitochondria such as electron transport system and TCA cycle. It has been found to be effective in treating cancer by a putative mechanism that improves the activity and evokes the system of Bax and Bak and causes apoptosis of caspase type IX when it has an unrecoverable nuclear abnormality (patented (patented) Literature 2)
- Non-Patent Document 4 It is known that this bilirubin and carbon monoxide have high antioxidant activity and can eliminate reactive oxygen species (ROS) directly and indirectly (Non-patent Document 5).
- ROS reactive oxygen species
- ALA along with any SFC, is known to have immune tolerance suppressing effects.
- This mechanism is that, in dendritic cells that are antigen-presenting cells, the above-mentioned HO-1 (or bilirubin and carbon monoxide) causes dendritic cells to change (differentiate) into cells called tolerogenic dendritic cells. It is believed that. Tolerogenic cells highly express PD-L1 and are known to perform specific immune tolerance (suppression of immunity) to antigens presented to T cells, and in fact, administration of ALA and SFC Thus, an increase in PD-L1 mRNA is observed in cells regarded as dendritic cells (Non-patent Document 6).
- a cancer therapeutic agent containing an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient is created, and further, a combination therapy of these cancer therapeutic agent and an existing drug attracts attention.
- clinical trials are planned for combined use of the above-mentioned signaling mimicking drug (hyperlipidemia drug Bezafibrate activating transcription factor PPARs) and anti-PD-1 antibody. That is, search and creation of pharmaceuticals and pharmaceutical compositions that can be highly correlated with immune checkpoint inhibitors such as anti-PD-1 antibody or anti-PD-L1 antibody and that can enhance the anti-tumor effect of the immune checkpoint inhibitor It is requested.
- the present invention aims to provide a pharmaceutical composition for enhancing the antitumor effect of an immune checkpoint inhibitor such as anti-PD-1 antibody or anti-PD-L1 antibody.
- ALA 5-aminolevulinic acid
- an immune check inhibitor such as anti-PD-1 antibody or anti-PD-L1 antibody
- ALA increases PD-L1-expressing dendritic cells or T cells
- a pharmaceutical composition for enhancing the anti-tumor effect of an immune checkpoint inhibitor comprising: The following formula (I): (Wherein, R 1 represents a hydrogen atom or an acyl group, and R 2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group or an aralkyl group) And a salt or ester thereof, Pharmaceutical composition.
- the pharmaceutical composition according to [1], wherein The immune checkpoint inhibitor comprises anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA4 antibody, anti-B7 antibody, anti-C27 antibody, anti-KIR antibody, IDO inhibitor, anti-CD137 antibody, and anti-TIM3 antibody At least one selected from the group: Pharmaceutical composition.
- composition according to [2] which is The immune checkpoint inhibitor is characterized in that it is an anti-PD-L1 antibody or an anti-PD-1 antibody Pharmaceutical composition.
- the pharmaceutical composition according to [1], wherein The above immune checkpoint inhibitors include atezolizumab (Atezolizumab), durvalumab (Durvalumab), avelumab (Avelumab), nivolumab (Nivolumab), pembrolizumab (Pembrolizumab), pidilizumab, BMS-936559, ipilimumab (pilimumab) Selected from the group consisting of Tremelimumab (tremelimumab), Enoblituzumab (Enoblituzumab), Vallilabb (Varlilumab), Lilylimumab (Lirilumab), Epacadostat (Epacadostat), Utomilumab (Utomilumab), Urelumab (Urelumab), and TSR-022, Pharmaceutical composition.
- R 1 is selected from the group consisting of a hydrogen atom, an alkanoyl group having 1 to 8 carbon atoms, and an aroyl group having 7 to 14 carbon atoms
- R 2 represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms, an aryl group having 6 to 14 carbon atoms, and an aralkyl having 7 to 15 carbon atoms Characterized in that it is selected from the group consisting of Pharmaceutical composition.
- composition according to any one of [1] to [8], which It further contains one or more metal-containing compounds, Pharmaceutical composition.
- the pharmaceutical composition according to [8], which The metal-containing compound is a compound containing iron, magnesium, zinc, nickel, vanadium, copper, chromium, molybdenum or cobalt, Pharmaceutical composition.
- a pharmaceutical composition according to [9], which comprises The metal-containing compound is a compound containing iron, magnesium or zinc, Pharmaceutical composition.
- a pharmaceutical composition according to [10], which comprises The metal-containing compound is a compound containing iron, Pharmaceutical composition.
- a method for enhancing the antitumor effect of an immune checkpoint inhibitor which comprises the following formula (I): (Wherein, R 1 represents a hydrogen atom or an acyl group, and R 2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group or an aralkyl group)
- R 1 represents a hydrogen atom or an acyl group
- R 2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group or an aralkyl group
- a pharmaceutical composition for enhancing the anti-tumor effect of an immune checkpoint inhibitor for enhancing the anti-tumor effect of an immune checkpoint inhibitor.
- FIG. 1 shows the administration schedule of each test agent in the test of Example 1.
- FIG. 2 shows a comparison of untreated group, anti-PD-L1 antibody administered group, anti-PD-L1 antibody + ALA administered group and anti-PD-L1 antibody + ALA + SFC administered group in tumor volume after tumor inoculation. * Indicates that p ⁇ 0.05 by t-test when the variances of the two populations are not equal.
- FIG. 3 shows the administration schedule of each test drug in the test of Example 2.
- FIG. 4 shows a comparison of untreated group, anti-PD-1 antibody administered group, and anti-PD-1 antibody + ALA + SFC administered group in tumor volume after tumor inoculation.
- the present invention relates to a pharmaceutical composition for enhancing the antitumor effect of an immune checkpoint inhibitor (hereinafter also referred to as "the pharmaceutical composition of the present invention").
- Immune checkpoint inhibitor is an anticancer agent that suppresses the growth of cancer by binding to an immune checkpoint molecule that suppresses the activity of T cells by antigen presentation and inhibiting its signal transduction.
- Immune checkpoint molecules can include both receptors and ligands that function as immune checkpoints.
- immunoreactive checkpoint inhibitors include, but are not limited to, for example, the binding or interaction between PD-1L and PD-1, CD80 / CD86 and CTLA4. Binding or interaction between CD137L and CD137, binding or interaction between MHC and LAG-3 / KIR, binding or interaction between CD48 and CD244, binding or interaction between GAL9 and TIM3 Action, binding or interaction between HVEM and BTLA / CD160, binding or interaction between CD40L and CD40, binding or interaction between OX40L and OX40, and binding or interaction between GITRL and GITR can be inhibited Any antibody or compound is included.
- the “immune checkpoint inhibitor” is, but not limited to, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, an anti-B7 antibody, an anti-C27 It is selected from the group consisting of an antibody, an anti-KIR antibody, an IDO inhibitor, an anti-CD137 antibody, and an anti-TIM3 antibody.
- the "immune checkpoint inhibitor” is not limited to atezolizumab (Atezolizumab), durvalumab (Durvalumab), avelumab (Avelumab), nivolumab (Nivolumab), pembrolizumab (Pembrolizumab), Pizirizumab (Pidilizumab), BMS-936559, Ipilimumab (Ipilimumab), Tremelimumab (tremelimumab), Enoblituzumab (Enoblituzumab), Vallilumab (Varlilumab), Lilimab (Lirilumab), etapoplatinum, Ur lumab), and it is selected from the TSR-022.
- the "immune checkpoint inhibitor” is an anti-PD-L1 antibody or an anti-PD-1 antibody.
- the pharmaceutical composition of the present invention is characterized in that ALA or a derivative, salt or ester thereof (hereinafter also simply referred to as "ALA”) is used as an active ingredient.
- ALA a derivative, salt or ester thereof
- ALA means 5-aminolevulinic acid.
- ALA also referred to as ⁇ -aminolevulinic acid, is one of the amino acids.
- R 1 represents a hydrogen atom or an acyl group
- R 2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group or an aralkyl group.
- ALA corresponds to the case where R 1 and R 2 are hydrogen atoms.
- ALAs may act as an active ingredient in the form of ALA of formula (I) or a derivative thereof in vivo, and can also be administered as a prodrug (precursor) that is degraded by enzymes in vivo.
- the acyl group in R 1 of the formula (I) includes linear or branched C 1-8 straight or branched carbon atoms such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, octanoyl, benzylcarbonyl group and the like Examples thereof include an alkanoyl group, and an aroyl group having 7 to 14 carbon atoms such as benzoyl, 1-naphthoyl and 2-naphthoyl groups.
- alkyl group in R 2 of the formula (I) linear such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl and octyl group or Examples thereof include branched alkyl groups having 1 to 8 carbon atoms.
- cycloalkyl group in R 2 of formula (I) a saturated or partially unsaturated bond such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclododecyl, 1-cyclohexenyl group and the like is present And a cycloalkyl group having 3 to 8 carbon atoms which may be mentioned.
- Examples of the aryl group in R 2 of the formula (I) include aryl groups having 6 to 14 carbon atoms such as phenyl, naphthyl, anthryl and phenanthryl groups.
- the aryl moiety may be the same as the above aryl group, and the alkyl moiety may be the same as the above alkyl group.
- Preferred ALA derivatives include compounds in which R 1 is formyl, acetyl, propionyl, butyryl and the like.
- Preferred examples of ALA derivatives include compounds in which R 2 is methyl, ethyl, propyl, butyl, pentyl and the like.
- a combination of the R 1 and R 2 is (formyl and methyl), (acetyl and methyl), (propionyl and methyl), (butyryl and methyl), (formyl and ethyl), (acetyl And ethyl), (propionyl and ethyl), and (butyryl and ethyl) in combination.
- each mineral acid salt such as hydrochloride, hydrobromide, hydroiodide, phosphate, nitrate, sulfate and the like, formate, acetate, propionate, toluenesulfonic acid Salt, succinate, oxalate, lactate, tartrate, glycolate, methanesulfonate, butyrate, valerate, citrate, fumarate, maleate, malate, etc.
- Organic acid addition salts can be exemplified.
- metal salts include alkali metal salts such as lithium salts, sodium salts and potassium salts, alkaline earth metal salts such as magnesium and calcium salts, and metal salts such as aluminum and zinc.
- ammonium salts include ammonium salts and alkyl ammonium salts such as tetramethyl ammonium salt.
- organic amine salt include salts such as triethylamine salt, piperidine salt, morpholine salt, toluidine salt and the like. In addition, these salts can also be used as a solution at the time of use.
- esters of ALAs include, but are not limited to, methyl ester, ethyl ester, propyl ester, butyl ester, pentyl ester and the like.
- ALA a monovalent fatty acid
- various esters such as ALA methyl ester, ALA ethyl ester, ALA propyl ester, ALA butyl ester, ALA pentyl ester, and their hydrochlorides, phosphoric acid It is salt, sulfate.
- ALA hydrochloride and ALA phosphate can be exemplified as particularly preferable ones.
- the above-mentioned ALA can be produced by known methods such as chemical synthesis, production by microorganisms, production by enzymes, and the like.
- the above ALAs may form hydrates or solvates, and may be used alone or in combination of two or more.
- one or more metal-containing compounds are used in combination.
- the pharmaceutical composition of the present invention may further contain one or more metal-containing compounds.
- the metal part of such metal-containing compounds include iron, magnesium, zinc, nickel, vanadium, cobalt, copper, chromium and molybdenum.
- the metal part of the metal-containing compound is iron, magnesium or zinc, in particular iron.
- the iron compound may be an organic salt or an inorganic salt.
- the inorganic salt include ferric chloride, ferric oxide, iron sulfate and ferrous pyrophosphate.
- organic salts carboxylates such as hydroxycarboxylates, ferrous citrate, sodium ferrous citrate, sodium ferrous citrate (SFC), citrates such as ferric ammonium ammonium, pyrophosphate Diiron, heme iron, dextran iron, iron lactate, ferrous gluconate, sodium diethylene triamine pentaacetate, ammonium diethylenetriamine pentaacetate, iron sodium ethylenediaminetetraacetate, iron ethylenediaminepentaacetate, iron ammonium ethylenediaminepentaacetate, sodium dicarboxymethyl glutamate, disodium Organic acid salts such as ferric ammonium carboxymethyl glutamate, ferrous fumarate, iron acetate, iron oxalate, ferrous succinate, ferrous succinate, ferrous
- examples of magnesium compounds include magnesium citrate, magnesium benzoate, magnesium acetate, magnesium oxide, magnesium oxide, magnesium chloride, magnesium hydroxide, magnesium carbonate, magnesium sulfate, magnesium silicate, magnesium silicate, magnesium nitrate, diethylenetriaminepentaacetic acid magnesium diammonium, Mention may be made of ethylenediaminetetraacetate magnesium disodium and magnesium protoporphyrin.
- examples of zinc compounds include zinc chloride, zinc oxide, zinc nitrate, zinc carbonate, zinc sulfate, diethylenetriaminepentaacetic acid zinc diammonium, ethylenediaminetetraacetic acid zinc disodium, zinc protoporphyrin, zinc-containing yeast .
- the dose of the metal-containing compound to the subject may be 0 to 100 times, preferably 0.01 to 10 times the molar dose of ALA to the subject, and preferably 0.1 to 8 times Is more desirable.
- the ALAs and the metal-containing compound contained in the pharmaceutical composition of the present invention can be administered either as a composition containing the ALAs and the metal-containing compound, or each can be administered alone, but even when each is administered alone It is preferable to simultaneously administer, and not only simultaneous administration is performed at the same time, but administration of ALAs and the metal-containing compound exerts additive effects, preferably synergistic effects, even at the same time. In order to be able to, it means that it is done without a considerable interval between the two.
- the administration route of the ALAs and the metal-containing compound in the present invention is not limited, and may be systemic administration or local administration.
- the administration route may be, for example, oral administration including sublingual administration, or inhalation administration, intravenous administration including intravenous drip, transdermal administration by patch, etc., suppository, or naso-gastric tube, nasal intestinal tract, gastric fistula tube Or parenteral administration such as administration by forced enteral feeding using an intestinal fistula tube.
- ALAs and metal-containing compounds may be administered from different routes.
- the dosage form of the pharmaceutical composition of the present invention may be appropriately determined depending on the administration route, and is not limited to, but is not limited to injections, drips, tablets, capsules, fine granules, powders, solutions, syrups, etc. There may be mentioned dissolved solutions, patches, suppositories and the like.
- the pharmaceutical composition according to the present invention may contain other optional ingredients such as other medicinal ingredients, nutritional agents, carriers and the like as needed.
- optional ingredient for example, conventional pharmaceutically acceptable carriers, binders, such as crystalline cellulose, gelatin, lactose, starch, magnesium stearate, talc, vegetable and animal fats, oils and fats, gums, polyalkylene glycols, etc.
- Additives such as stabilizers, solvents, dispersion media, bulking agents, excipients, diluents, pH buffers, disintegrants, solubilizers, solubilizers, isotonic agents, etc. it can.
- the administration subjects of the pharmaceutical composition of the present invention are subjects to which an immune checkpoint inhibitor is administered or administered, typically subjects suffering from cancer.
- the type of cancer to be treated may vary depending on the immune checkpoint inhibitor used.
- the dose of ALAs to be administered by the pharmaceutical composition of the present invention is ALA equivalent per kg body weight of the subject (ie, in the formula (I), R), depending on the subject's height, weight, age and symptoms.
- the dose can be administered in the range of 1 mg to 1,000 mg, preferably 5 mg to 100 mg, more preferably 10 mg to 30 mg, still more preferably 15 mg to 25 mg, in terms of mass when 1 and R 2 are hydrogen atoms.
- the frequency and frequency of administration of the pharmaceutical composition of the present invention may be determined appropriately by those skilled in the art in view of the administration situation (interval, frequency and duration of administration) of the combined immune checkpoint inhibitor.
- the frequency can be determined.
- the pharmaceutical composition of the present invention is administered on a daily basis before, at, or after administration of the immune checkpoint inhibitor.
- the pharmaceutical composition of the present invention and the immune checkpoint inhibitor can be administered to the subject simultaneously, at different times, sequentially or at intervals, the effective amounts of each.
- the pharmaceutical composition of the present invention and the immune checkpoint inhibitor may be administered to tumor patients in the same administration cycle or may be administered in separate administration cycles. In one embodiment of the invention, the pharmaceutical composition of the invention and the immune checkpoint inhibitor are each administered in separate administration cycles.
- administration of the pharmaceutical composition of the invention to a subject is initiated before administration of the immune checkpoint inhibitor is initiated.
- the pharmaceutical composition of the present invention can be administered daily from one week before the start of administration of the immune checkpoint inhibitor.
- the administration of the pharmaceutical composition of the present invention to the subject is started on the same day as the administration of the immune checkpoint inhibitor.
- the pharmaceutical composition of the present invention can be administered on a daily basis from the day of administration of the immune checkpoint inhibitor.
- the pharmaceutical composition of the present invention and the immune checkpoint inhibitor are simultaneously administered, they may be prepared and administered as a single preparation, or may be simultaneously administered by separate administration routes.
- administration of the pharmaceutical composition of the present invention to the subject is initiated after administration of the immune checkpoint inhibitor.
- the pharmaceutical composition of the present invention can be administered on a daily basis following administration of the immune checkpoint inhibitor.
- the onset time of the pharmaceutical composition of the present invention is not particularly limited as long as it can enhance the antitumor effect of the immune checkpoint inhibitor, it is preferably for a long time, for example, one month or more, from the onset of the immune checkpoint inhibitor. It is preferred that 3 weeks or more, more preferably 2 weeks or more, more preferably 10 days or more have not elapsed.
- mice were inoculated with 3 ⁇ 10 5 mouse melanoma cell line B16F10 in the flank and allowed to grow for 28 days.
- anti-mouse PD-L1 antibody (Clone: MIH5) for PD-L1 antibody alone administration group, anti-PD-L1 antibody + ALA administration group and anti-PD-L1 antibody + ALA + SFC administration group was administered intraperitoneally at 200 ⁇ g / head (FIG. 1).
- ALA hydrochloride (neo ALA Co., Ltd.) 100 mg / kg and ferrous sodium citrate (SFC; Komatsu Co., Ltd.) once daily from day 10 to day 16 of inoculation B) 157 mg / kg orally.
- SFC ferrous sodium citrate
- 100 mg / kg of ALA hydrochloride (neo ALA Co., Ltd.) was orally administered once daily from day 10 to day 16 of inoculation.
- the effect of the anti-PD-L1 antibody was more pronounced when SFC was further administered in addition to ALA (anti-PD-L1 antibody + ALA + SFC administration group). This result indicates that the combination of ALA + SFC enhances the antitumor effect of the anti-PD-L1 antibody, and is expected to contribute to further prolonging the survival rate of mice.
- mice were inoculated in the flank with 3 ⁇ 10 5 mouse melanoma cell line B16F10, and tumors were allowed to grow for 16 days.
- anti-mouse PD-1 antibody (Clone: RMP1-) for the PD-1 antibody alone administration group, the anti-PD-1 antibody + ALA administration group and the anti-PD-1 antibody + ALA + SFC administration group. 14) was intraperitoneally administered at 200 ⁇ g / head (FIG. 3).
- ALA hydrochloride (neo ALA Co., Ltd.) 100 mg / kg and ferrous sodium citrate (SFC; Komatsu Co., Ltd.) once daily from the 8th to the 16th day of inoculation B) 157 mg / kg orally.
- SFC ferrous sodium citrate
- the N number is 18 in the control group (10 survive on day 16), 10 on the anti-PD-1 antibody alone group (overall survival on day 16), 10 in the anti-PD-1 antibody + ALA + SFC administration group (9 animals survived at day 16).
- a pharmaceutical composition for enhancing the anti-tumor effect of an immune checkpoint inhibitor there is provided a pharmaceutical composition for enhancing the anti-tumor effect of an immune checkpoint inhibitor. Therefore, it is expected that the combined use of the immune checkpoint inhibitor and the pharmaceutical composition according to the present invention leads to an increase in survival and remission rate of cancer patients.
- ALAs which are active ingredients of the pharmaceutical composition according to the present invention, are a kind of natural amino acids contained in animals, plants, fungi, etc. widely present, they can be safely used for living bodies. It has the advantage of
Abstract
Description
[1] 免疫チェックポイント阻害剤の抗腫瘍効果を増強するための医薬組成物であって、
下記式(I):
で示される化合物またはその塩もしくはエステルを含む、
医薬組成物。
前記免疫チェックポイント阻害剤は、抗PD-1抗体、抗PD-L1抗体、抗CTLA4抗体、抗B7抗体、抗C27抗体、抗KIR抗体、IDO阻害薬、抗CD137抗体、および抗TIM3抗体よりなる群から選択される少なくとも1種である、
医薬組成物。
免疫チェックポイント阻害剤は、抗PD-L1抗体または抗PD-1抗体である
ことを特徴とする、
医薬組成物。
前記免疫チェックポイント阻害剤は、アテゾリズマブ(Atezolizumab)、デュルバルマブ(Durvalumab)、アベルマブ(Avelumab)、ニボルマブ(Nivolumab)、ペムブロリズマブ(Pembrolizumab)、ピジリズマブ(Pidilizumab)、BMS-936559、イピリムマブ(Ipilimumab)、
トレメリムマブ(tremelimumab)、エノブリツズマブ(Enoblituzumab)、ヴァルリルマブ(Varlilumab)、リリルマブ(Lirilumab)、エパカドスタット(Epacadostat)、ウトミルマブ(Utomilumab)、ウレルマブ(Urelumab)、およびTSR-022よりなる群から選択される、
医薬組成物。
免疫チェックポイント阻害剤と同時または異時に投与される
ことを特徴とする、
医薬組成物。
R1が、水素原子、炭素数1~8のアルカノイル基、および、炭素数7~14のアロイル基からなる群から選択され、
R2が、水素原子、直鎖または分岐状の炭素数1~8のアルキル基、炭素数3~8のシクロアルキル基、炭素数6~14のアリール基、および、炭素数7~15のアラルキル基からなる群から選択される
ことを特徴とする、
医薬組成物。
R1およびR2が、水素原子である、
医薬組成物。
一種または二種以上の金属含有化合物をさらに含有する、
医薬組成物。
金属含有化合物が、鉄、マグネシウム、亜鉛、ニッケル、バナジウム、銅、クロム、モリブデンまたはコバルトを含有する化合物である、
医薬組成物。
金属含有化合物が、鉄、マグネシウムまたは亜鉛を含有する化合物である、
医薬組成物。
金属含有化合物が、鉄を含有する化合物である、
医薬組成物。
前記鉄を含有する化合物が、クエン酸第一鉄ナトリウムである、
医薬組成物。
で示される化合物またはその塩もしくはエステルの使用。
で示される化合物またはその塩もしくはエステルを、免疫チェックポイント阻害剤が投与されるまたは投与されている対象に投与することを含む、
方法。
本発明は、免疫チェックポイント阻害剤による抗腫瘍効果を増強するための医薬組成物(以下、「本発明の医薬組成物」とも称する。)に関する。
C57BL/6マウスに対し、マウスメラノーマ細胞株B16F10を3×105個を脇腹に接種し、28日間腫瘍を成長させた。接種10日目および15日目の時点で、PD-L1抗体単独投与群、抗PD-L1抗体+ALA投与群および抗PD-L1抗体+ALA+SFC投与群について、抗マウスPD-L1抗体(Clone:MIH5)を200μg/headで腹腔内に投与した(図1)。抗PD-L1抗体+ALA+SFC投与群については、接種10日目から16日目まで毎日1回ALA塩酸塩(neo ALA株式会社)100 mg/kgとクエン酸第一鉄ナトリウム(SFC;小松屋株式会社)157mg/kgとを経口投与した。また、および抗PD-L1抗体+ALA投与群については、接種10日目から16日目まで毎日1回ALA塩酸塩(neo ALA株式会社)100mg/kgを経口投与した。対照群として接種後無処置の群を置いた。
2日に一度腫瘍径を測定し、v=(短径.mm)2×(長径.mm)/2としたときのvを、腫瘍体積(mm3)として記録した。N数は、対照群13匹(16日目時点で8匹が生存)、抗PD-L1抗体単独群10匹(16日目時点で9匹が生存)、抗PD-L1抗体+ALA投与群4匹(16日目時点で全匹生存)、抗PD-L1抗体+ALA+SFC投与群9匹(16日目時点で全匹生存)であった。
結果
接種16日の時点で、抗PD-L1抗体+ALA投与群は、抗PD-L1抗体単独群と比較して明らかに腫瘍体積が小さかった(図2)。また、抗PD-L1抗体による効果は、ALAに加えてさらにSFCを投与した場合に、より顕著であった(抗PD-L1抗体+ALA+SFC投与群)。この結果は、ALA+SFCの併用により、抗PD-L1抗体の抗腫瘍効果が増強されることを示しており、マウスの生存率のさらなる延長に寄与することが期待される。
C57BL/6マウスに対し、3×105個のマウスメラノーマ細胞株B16F10を脇腹に接種し、16日間腫瘍を成長させた。接種8日目および12日目の時点で、PD-1抗体単独投与群、抗PD-1抗体+ALA投与群および抗PD-1抗体+ALA+SFC投与群について、抗マウスPD-1抗体(Clone:RMP1-14)を200μg/headで腹腔内に投与した(図3)。抗PD-1抗体+ALA+SFC投与群については、接種8日目から16日目まで毎日1回ALA塩酸塩(neo ALA株式会社)100 mg/kgとクエン酸第一鉄ナトリウム(SFC;小松屋株式会社)157mg/kgとを経口投与した。対照群として接種後無処置の群を置いた。
2日に一度腫瘍径を測定し、v=(短径.mm)2×(長径.mm)/2としたときのvを、腫瘍体積(mm3)として記録した。N数は、対照群18匹(16日目時点で10匹が生存)、抗PD-1抗体単独群10匹(16日目時点で全匹生存)、抗PD-1抗体+ALA+SFC投与群10匹(16日目時点で9匹生存)であった。
結果
接種16日の時点で、抗PD-1抗体+ALA+SFC投与群は、抗PD-1抗体単独群と比較して明らかに腫瘍体積が小さかった(図4)。この結果は、ALA+SFCの併用により、抗PD-1抗体の抗腫瘍効果が増強されることを示しており、マウスの生存率のさらなる延長に寄与することが期待される。
また、本発明に係る医薬組成物の有効成分であるALA類は、動物、植物、菌類など広く存在する、生体内に含まれる天然アミノ酸の一種であることから、生体に対して安全に使用できるという利点を有する。
Claims (14)
- 請求項1に記載の医薬組成物であって、
前記免疫チェックポイント阻害剤は、抗PD-1抗体、抗PD-L1抗体、抗CTLA4抗体、抗B7抗体、抗C27抗体、抗KIR抗体、IDO阻害薬、抗CD137抗体、および抗TIM3抗体よりなる群から選択される少なくとも1種である、
医薬組成物。 - 請求項2に記載の医薬組成物であって、
免疫チェックポイント阻害剤は、抗PD-L1抗体または抗PD-1抗体である
ことを特徴とする、
医薬組成物。 - 請求項1に記載の医薬組成物であって、
前記免疫チェックポイント阻害剤は、アテゾリズマブ(Atezolizumab)、デュルバルマブ(Durvalumab)、アベルマブ(Avelumab)、ニボルマブ(Nivolumab)、ペムブロリズマブ(Pembrolizumab)、ピジリズマブ(Pidilizumab)、BMS-936559、イピリムマブ(Ipilimumab)、
トレメリムマブ(tremelimumab)、エノブリツズマブ(Enoblituzumab)、ヴァルリルマブ(Varlilumab)、リリルマブ(Lirilumab)、エパカドスタット(Epacadostat)、ウトミルマブ(Utomilumab)、ウレルマブ(Urelumab)、およびTSR-022よりなる群から選択される、
医薬組成物。 - 請求項1~4のいずれか1項に記載の医薬組成物であって、
免疫チェックポイント阻害剤と同時または異時に投与される
ことを特徴とする、
医薬組成物。 - 請求項1~5のいずれか1項に記載の医薬組成物であって、
R1が、水素原子、炭素数1~8のアルカノイル基、および、炭素数7~14のアロイル基からなる群から選択され、
R2が、水素原子、直鎖または分岐状の炭素数1~8のアルキル基、炭素数3~8のシクロアルキル基、炭素数6~14のアリール基、および、炭素数7~15のアラルキル基からなる群から選択される
ことを特徴とする、
医薬組成物。 - 請求項1~6のいずれか1項に記載の医薬組成物であって、
R1およびR2が、水素原子である、
医薬組成物。 - 請求項1~7のいずれか1項に記載の医薬組成物であって、
一種または二種以上の金属含有化合物をさらに含有する、
医薬組成物。 - 請求項8に記載の医薬組成物であって、
金属含有化合物が、鉄、マグネシウム、亜鉛、ニッケル、バナジウム、銅、クロム、モリブデンまたはコバルトを含有する化合物である、
医薬組成物。 - 請求項9に記載の医薬組成物であって、
金属含有化合物が、鉄、マグネシウムまたは亜鉛を含有する化合物である、
医薬組成物。 - 請求項10に記載の医薬組成物であって、
金属含有化合物が、鉄を含有する化合物である、
医薬組成物。 - 請求項11に記載の医薬組成物であって、
前記鉄を含有する化合物が、クエン酸第一鉄ナトリウムである、
医薬組成物。
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3079496A CA3079496C (en) | 2017-12-01 | 2018-11-28 | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
US16/651,238 US11266619B2 (en) | 2017-12-01 | 2018-11-28 | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
AU2018377785A AU2018377785B2 (en) | 2017-12-01 | 2018-11-28 | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
CN201880065357.4A CN111417390A (zh) | 2017-12-01 | 2018-11-28 | 用于增强免疫检查点抑制剂之抗肿瘤作用的药物组合物 |
BR112020010839-1A BR112020010839A2 (pt) | 2017-12-01 | 2018-11-28 | composição farmacêutica para intensificar o efeito antitumoral por inibidor de ponto de verificação imunológico e uso de composto na produção de um medicamento para intensificar o referido efeito antitumoral |
RU2020121523A RU2760132C1 (ru) | 2017-12-01 | 2018-11-28 | Фармацевтическая композиция для усиления противоопухолевого эффекта ингибитора иммунной контрольной точки |
KR1020207018437A KR102214029B1 (ko) | 2017-12-01 | 2018-11-28 | 면역 체크포인트 억제제에 의한 항종양 효과를 증강시키기 위한 제약 조성물 |
MX2020005692A MX2020005692A (es) | 2017-12-01 | 2018-11-28 | Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario. |
JP2019524476A JP6617220B2 (ja) | 2017-12-01 | 2018-11-28 | 免疫チェックポイント阻害剤による抗腫瘍効果を増強するための医薬組成物 |
NZ765602A NZ765602B2 (en) | 2017-12-01 | 2018-11-28 | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
EP18882989.9A EP3673904A4 (en) | 2017-12-01 | 2018-11-28 | PHARMACEUTICAL COMPOSITION FOR THE REINFORCEMENT OF AN ANTI-TUMOR EFFECT BY AN INHIBITOR OF IMMUNE CONTROL POINTS |
TW108117257A TW202019488A (zh) | 2017-12-01 | 2019-05-20 | 用於增強藉由免疫檢查點抑制劑之抗腫瘤效果之醫藥組成物 |
PH12020550124A PH12020550124A1 (en) | 2017-12-01 | 2020-03-24 | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
US17/682,413 US20220249417A1 (en) | 2017-12-01 | 2022-02-28 | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017231449 | 2017-12-01 | ||
JP2017-231449 | 2017-12-01 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/651,238 A-371-Of-International US11266619B2 (en) | 2017-12-01 | 2018-11-28 | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
US17/682,413 Continuation US20220249417A1 (en) | 2017-12-01 | 2022-02-28 | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019107389A1 true WO2019107389A1 (ja) | 2019-06-06 |
Family
ID=66665041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/043704 WO2019107389A1 (ja) | 2017-12-01 | 2018-11-28 | 免疫チェックポイント阻害剤による抗腫瘍効果を増強するための医薬組成物 |
Country Status (14)
Country | Link |
---|---|
US (2) | US11266619B2 (ja) |
EP (1) | EP3673904A4 (ja) |
JP (2) | JP6617220B2 (ja) |
KR (1) | KR102214029B1 (ja) |
CN (1) | CN111417390A (ja) |
AU (1) | AU2018377785B2 (ja) |
BR (1) | BR112020010839A2 (ja) |
CA (1) | CA3079496C (ja) |
MX (1) | MX2020005692A (ja) |
MY (1) | MY181242A (ja) |
PH (1) | PH12020550124A1 (ja) |
RU (1) | RU2760132C1 (ja) |
TW (1) | TW202019488A (ja) |
WO (1) | WO2019107389A1 (ja) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5611548B2 (ja) | 1976-12-27 | 1981-03-14 | ||
JP2011016753A (ja) * | 2009-07-08 | 2011-01-27 | Sbi Alapromo Co Ltd | 5−アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とするがんの予防・改善剤 |
WO2015129535A1 (ja) * | 2014-02-25 | 2015-09-03 | 学校法人産業医科大学 | 腫瘍免疫誘導用組成物 |
JP5885764B2 (ja) | 2002-07-03 | 2016-03-15 | 小野薬品工業株式会社 | 癌治療剤 |
WO2017103283A1 (en) * | 2015-12-17 | 2017-06-22 | Photocure Asa | Neoadjuvant therapy for bladder cancer |
WO2017103280A1 (en) * | 2015-12-17 | 2017-06-22 | Photocure Asa | Intravesical therapy for bladder cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10110107A (ja) | 1996-10-04 | 1998-04-28 | Fuji Photo Film Co Ltd | 新規メチン化合物及び該化合物を含むハロゲン化銀写真感光材料 |
EP3192506A3 (en) | 2008-10-27 | 2017-10-25 | SBI Pharmaceuticals Co., Ltd. | Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative or 5-aminolevulinic acid as active ingredient |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
US20120134921A1 (en) | 2009-06-11 | 2012-05-31 | Photocure Asa | Solid compositions comprising 5-aminolevulinic acid |
JP2012012305A (ja) | 2010-06-29 | 2012-01-19 | Kanazawa Univ | 抗がん剤の作用増強剤 |
JP5818906B2 (ja) | 2011-10-12 | 2015-11-18 | Sbiファーマ株式会社 | 抗ガン剤の副作用の予防剤及び/又は治療剤 |
US10314854B2 (en) * | 2015-05-15 | 2019-06-11 | University Of Iowa Foundation | Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy |
-
2018
- 2018-11-28 WO PCT/JP2018/043704 patent/WO2019107389A1/ja unknown
- 2018-11-28 MY MYPI2020002713A patent/MY181242A/en unknown
- 2018-11-28 CA CA3079496A patent/CA3079496C/en active Active
- 2018-11-28 AU AU2018377785A patent/AU2018377785B2/en active Active
- 2018-11-28 RU RU2020121523A patent/RU2760132C1/ru active
- 2018-11-28 JP JP2019524476A patent/JP6617220B2/ja active Active
- 2018-11-28 US US16/651,238 patent/US11266619B2/en active Active
- 2018-11-28 BR BR112020010839-1A patent/BR112020010839A2/pt not_active Application Discontinuation
- 2018-11-28 EP EP18882989.9A patent/EP3673904A4/en active Pending
- 2018-11-28 KR KR1020207018437A patent/KR102214029B1/ko active IP Right Grant
- 2018-11-28 CN CN201880065357.4A patent/CN111417390A/zh active Pending
- 2018-11-28 MX MX2020005692A patent/MX2020005692A/es unknown
-
2019
- 2019-05-20 TW TW108117257A patent/TW202019488A/zh unknown
- 2019-08-06 JP JP2019144461A patent/JP2019182882A/ja active Pending
-
2020
- 2020-03-24 PH PH12020550124A patent/PH12020550124A1/en unknown
-
2022
- 2022-02-28 US US17/682,413 patent/US20220249417A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5611548B2 (ja) | 1976-12-27 | 1981-03-14 | ||
JP5885764B2 (ja) | 2002-07-03 | 2016-03-15 | 小野薬品工業株式会社 | 癌治療剤 |
JP2011016753A (ja) * | 2009-07-08 | 2011-01-27 | Sbi Alapromo Co Ltd | 5−アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とするがんの予防・改善剤 |
WO2015129535A1 (ja) * | 2014-02-25 | 2015-09-03 | 学校法人産業医科大学 | 腫瘍免疫誘導用組成物 |
WO2017103283A1 (en) * | 2015-12-17 | 2017-06-22 | Photocure Asa | Neoadjuvant therapy for bladder cancer |
WO2017103280A1 (en) * | 2015-12-17 | 2017-06-22 | Photocure Asa | Intravesical therapy for bladder cancer |
Non-Patent Citations (11)
Title |
---|
AM J PHYSIOL CELL PHYSIOL., vol. 308, no. 8, 15 April 2015 (2015-04-15), pages C665 - 72 |
AM J PHYSIOL RENAL PHYSIOL., vol. 305, no. 8, 15 October 2013 (2013-10-15), pages F1149 - 57 |
ANN TRANSL MED., vol. 3, no. 18, October 2015 (2015-10-01), pages 267 |
HOU, J. ET AL.: "5-aminolevulinic acid with ferrous iron induces permanent cardiac allograft acceptance in mice via induction of regulatory cells", J HEART LUNG TRANSPLANT, vol. 34, no. 2, 2015, pages 254 - 263, XP029220929, DOI: 10.1016/j.healun.2014.09.037 * |
J HEART LUNG TRANSPLANT., vol. 34, no. 2, February 2015 (2015-02-01), pages 254 - 63 |
KEE, D. ET AL.: "Immunotherapy of melanoma", EUR J SURG ONCOL, vol. 43, no. 3, March 2017 (2017-03-01), pages 594 - 603, XP029914020, DOI: 10.1016/j.ejso.2016.07.014 * |
NAT REV CANCER., vol. 12, no. 4, 22 March 2012 (2012-03-22), pages 252 - 64 |
PROC NATL ACAD SCI USA., vol. 114, no. 5, 31 January 2017 (2017-01-31), pages E761 - E770 |
See also references of EP3673904A4 |
WANG, S. ET AL.: "5-aminolevulinic acid-mediated sonodynamic therapy reverses macrophage and dendritic cell passivity in murine melanoma xenografts", ULTRASOUND MED BIOL., vol. 40, no. 9, 2014, pages 2125 - 2133, XP55616078 * |
WATASE, ERIKA ET AL.: "Effects on the immune checkpoint factors by combination photodynamic therapy with aminolevulinic acid for malignant glioma", NIHON IKA DAIGAKU IGAKKAI ZASSHI, vol. 13, no. 4, October 2017 (2017-10-01), pages 248, XP009519894, DOI: 10.1272/manms.13.243 * |
Also Published As
Publication number | Publication date |
---|---|
KR102214029B1 (ko) | 2021-02-08 |
CA3079496A1 (en) | 2019-06-06 |
BR112020010839A2 (pt) | 2020-09-15 |
EP3673904A4 (en) | 2021-06-09 |
RU2760132C1 (ru) | 2021-11-22 |
PH12020550124A1 (en) | 2021-02-08 |
NZ765602A (en) | 2020-11-27 |
AU2018377785B2 (en) | 2020-10-01 |
US11266619B2 (en) | 2022-03-08 |
MY181242A (en) | 2020-12-21 |
JPWO2019107389A1 (ja) | 2019-12-12 |
KR20200085346A (ko) | 2020-07-14 |
MX2020005692A (es) | 2020-09-25 |
US20220249417A1 (en) | 2022-08-11 |
US20200297674A1 (en) | 2020-09-24 |
TW202019488A (zh) | 2020-06-01 |
AU2018377785A1 (en) | 2020-07-09 |
JP6617220B2 (ja) | 2019-12-11 |
EP3673904A1 (en) | 2020-07-01 |
CN111417390A (zh) | 2020-07-14 |
CA3079496C (en) | 2021-06-01 |
JP2019182882A (ja) | 2019-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201412306A (zh) | 流感病毒傳染病之預防治療劑 | |
WO2016163082A1 (ja) | Ala類を含むウイルス感染症予防/治療剤 | |
TWI543960B (zh) | Erythropoietin production accelerator | |
CN106474098B (zh) | 免疫耐受诱导剂 | |
WO2019107389A1 (ja) | 免疫チェックポイント阻害剤による抗腫瘍効果を増強するための医薬組成物 | |
JP6093428B2 (ja) | がん性貧血改善・予防剤 | |
NZ765602B2 (en) | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor | |
CA3024575A1 (en) | A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases | |
JP2021107352A (ja) | 豚コレラの治療及び/又は予防剤 | |
JP7478386B2 (ja) | プラズマ療法によるがんまたは腫瘍の治療効果を増強 | |
WO2010061907A1 (ja) | 抗癌剤 | |
WO2020090570A1 (ja) | 光障害低減剤 | |
JPH0673037A (ja) | 細胞増殖抑制剤療法用補助剤 | |
JPWO2021113212A5 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2019524476 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18882989 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018882989 Country of ref document: EP Effective date: 20200323 |
|
ENP | Entry into the national phase |
Ref document number: 3079496 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20207018437 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018377785 Country of ref document: AU Date of ref document: 20181128 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020010839 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112020010839 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200529 |